Program Leads Patients With Cancer on ‘The Right Track’
Cognitive Changes After Cancer Treatment
Life Expectancy With Cancer
Developing Second Cancers And How To Manage Them
September 24th 2020, 4:00pm
By Barbara Tako
You know yourself best, so try and figure out what works best for you and do not be afraid to give yourself the precious gift of self-care during and after your cancer journey. You deserve this.
September 24th 2020, 3:00pm
By Jessica Skarzynski
In this week’s episode of the CURE® Talks Cancer podcast, we chat with Dr. Tanja Gruber, the chief of pediatric hematology, oncology and stem cell transplantation at Stanford Children’s Health, about how pediatric cancer treatment is evolving thanks to advances in treatments like immunotherapy, and what parents should do after their child receives a diagnosis.
September 24th 2020, 1:00pm
By Ryan McDonald
Here is a list of some recent trials that launched within the cancer space in September.
September 23rd 2020, 9:00pm
By Beth Fand Incollingo
There is no approved treatment that targets the KRAS p.G12C mutation that drives some cancers like non-small cell lung cancer. But a recent study shows how the experimental drug sotorasib sparked responses in some patients with advanced non-small cell lung cancer that harbored the mutation.
September 23rd 2020, 7:18pm
By CURE Media Group
On Thursday, September 30, 2020, from 5:30 – 6:30 p.m. ET join CURE® for the next EDUCATED PATIENT® CLL Webinar.
September 23rd 2020, 6:00pm
By Meeri Kim
For years, childhood blood cancers were understudied forcing patients’ treatments into a one size-fits-all approach. But new efforts are changing that.
September 23rd 2020, 4:00pm
By Ronald Cooper
I suffered a recurrence a few years ago and couldn’t bear to hear, or utter, the word “cancer.” So, I decided to counter-attack by belittling the disease and calling it “chocolate.” Then, I got my sweet revenge.
September 23rd 2020, 3:00pm
By Dara Chadwick
Weighing the cost of CAR-T cell therapy in treating blood cancers is a finical burden for many patients with blood cancer.
September 23rd 2020, 1:00pm
By Kristie L. Kahl
The PARP inhibitor Lynparza reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer compared with Xtandi or Zytiga plus the corticosteroid prednisone.
September 22nd 2020, 9:00pm
Findings from a randomized phase 3 study showed that adding neoadjuvant Tecentriq to a chemotherapy regimen of Abraxane, Adriamycin and Cytoxan in patients with stage 2 or 3 triple-negative breast cancer significantly improved pathologic complete responses, compared with placebo plus chemotherapy.
